Genetics and susceptibility to toxic chemicals: Do you (or should you) know your genetic profile?

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 403-409

  Lash, Lawrence H ^a   Hines, Ronald N ^b   Gonzalez, Frank J ^c   Zacharewski, Timothy R ^d   Rothstein, Mark A ^e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Michigan State University   (United States)

^e University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CHOLINESTERASE; DEBRISOQUINE; DIMETHYLANILINE MONOOXYGENASE; GLUCURONOSYLTRANSFERASE; ISONIAZID; PARACETAMOL; SPARTEINE; SUXAMETHONIUM; THIOPURINE METHYLTRANSFERASE; XENOBIOTIC AGENT;

APNEA; DISEASE PREDISPOSITION; DNA MICROARRAY; DRUG EXPOSURE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; KNOCKOUT GENE; LIVER NECROSIS; METABOLIC CLEARANCE RATE; NEUROPATHY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRANSGENIC MOUSE;

ANIMALS; ENZYME INHIBITORS; ENZYMES; GENE EXPRESSION PROFILING; HAZARDOUS SUBSTANCES; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; XENOBIOTICS;

EID: 0037405757     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039925     Document Type: Review

References (47)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Wu X, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond) 403:503-511.
2. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, and Levine AJ (1999) Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96:6745-6750.
3. Brazma A, Robinson A, Cameron G, and Ashnurner M (2000) One-stop shop for microarray data. Nature (Lond) 403:699-700.
4. Burczynski ME, McMillan M, Ciervo J, Li L, Parker JB, Dunn RT 2nd, Hicken S, Farr S, and Johnson MD (2000) Toxicogenomics-based discrimination of toxic mechanisms in HepG2 human hepatoma cells. Toxicol Sci 58:399-415.
5. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, and Gonzalez FJ (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[α]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982.
6. Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, and Gonzalez FJ (1996) Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics 6:291-296.
7. Cook-Deegan RM (1989) The Alta summit, December, 1984. Genomics 5:661-663.
8. Dalton TP, Dieter MZ, Matlib RS, Childs NL, Shertzer HG, Genter MB, and Nebert DW (2000) Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 267:184-189.
9. DeLisi C (1988) Overview of human genome research. Basic Life Sci 46:5-10.
10. Eichelbaum M, Spannbrucker N, Steincke B, and Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic trait. Eur J Clin Pharmacol 16:183-187.
11. Fielden MR and Zacharewski TR (2001) Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 60:6-10.
12. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331:442-446.
13. Gorrod AE and Oxon MD (1902) The incidence of alkaptonuria: a study in chemical individuality. Lancet 1616-1620.
14. Halgren RG, Fielden MR, Fong CJ, and Zacharewski TR (2001) Assessment of clone identity and sequence fidelity for 1189 IMAGE cDNA clones. Nucleic Acid Res 29:582-588.
15. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L, Tennant R, Stoll R, Barrett JC, Paules RS, Blanchard K, and Afshari CA (2002a) Prediction of compound signature using high density gene expression profiling. Toxicol Sci 67:232-240.
16. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, Bennett L, Tennant R, Stoll R, Barrett JC, et al. (2002b) Gene Expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219-231.
17. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102:109-126.
18. Kerr MK and Churchill GA (2001) Statistical design and the analysis of gene expression microarray data. Genet Res 77:123-128.
19. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Res 51:236-243.
20. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, and Gonzalez FJ (1996) Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-12067.
21. Leeder JS (2001) Pharmacogenetics and pharmacogenomics. Pediatr Clin N Am 48:765-781.
22. Mahgoub A, Dring LG, Idle JR, Lancaster R, and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
23. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, et al. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 4:1293-1301.
24. Mayatepek E and Kohlmüller D (1998) Transient trimethylaminuria in childhood. Acta Paediatr 87:1205-1207.
25. McLeod HL and Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101-121.
26. Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, and Gonzalez FJ (1999) Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[α]anthracene. J Biol Chem 274:23963-23968.
27. Motulsky AG (1957) Drug reactions, enzymes and biochemical genetics. J Am Med Assn 165:835-837.
28. Nassif EG, Weinberger MM, Shannon D, Guiang SF, Hendeles L, Jimenez D, and Ekwo E (1981) J Pediatrics 98:159-161.
29. Nebert DW (1997) Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 7:435-440.
30. Nuwaysir EF, Bittner M, Trent J, Barrett JC, and Afshari CA (1999) Microarrays and toxicology: the advent of toxicogenomics. Mol Carinog 24:153-159.
31. Omenn GS and Gelboin HV (1984) Genetic Variability in Responses to Chemicals, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
32. Pan W (2002) A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics 18:546-554.
33. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, and Yang CS (1993) Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 6:511-518.
34. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96:9212-9217.
35. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, and Gonzalez FJ (1995) Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci USA 92:5134-5138.
36. Prasad JS, Chen NQ, Liu YX, Goon DJ, and Holtzman JL (1990) Effects of ethanol and inhibitors on the binding and metabolism of acetaminophen and N-acetyl-pbenzoquinone imine by hepatic microsomes from control and ethanol-treated rats. Biochem Pharmacol 40:1989-1995.
37. Rumack BH (2002) Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 40:3-20.
38. Seidegård J and Pero RW (1985) The hereditary transmission of high glutathione transferase activity toward trans-stilbene oxide in human mononuclear leukocytes. Human Genetics 69:66-68.
39. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
40. Snyder LH (1932) Studies in human inheritance. IX. The inheritance of taste deficiency in man. Ohio J Sci 32:436-438.
41. Sonnier M and Cresteil T (1998) Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893-898.
42. Taylor E, Cogdell D, Coombes K, Hu L, Ramdas L, Tabor A, Hamilton S, and Zhang W (2001) Sequence verification as quality-control step for production of cDNA microarrays. Biotechniques 31:62-65.
43. Vogel F (1959) Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 12:52-125.
44. Waring JF, Ciurlionis R, Jolly RA, Heïndel M, and Ulrich RG (2001a) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanistic toxicity. Toxicol Lett 120:359-368.
45. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, and Ulrich RG (2001b) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 175:28-42.
46. Weinshilboum RM and Sladek SL (1980) Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662.
47. Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, and Gonzalez FJ (1998) Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 152:193-199.